Business Context and Reporting Period
Company: Hercules Technology Growth Capital, Inc. (HTGC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2011
Business Overview: HTGC is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC) and a Regulated Investment Company (RIC). It provides debt and equity growth capital to technology-related companies, including life sciences, clean technology, and lower middle market technology firms. The company utilizes Small Business Investment Company (SBIC) subsidiaries (HT II and HT III) to leverage capital from the SBA.
Key Financial Metrics
| Metric (in thousands, except per share) | Sept 30, 2011 | Dec 31, 2010 |
|---|---|---|
| Total Assets | $688,637 | $591,247 |
| Total Investments (at value) | $576,477 | $472,032 |
| Cash and Cash Equivalents | $96,309 | $107,014 |
| Total Liabilities | $266,587 | $178,716 |
| Long-term SBA Debentures | $188,750 | $170,000 |
| Convertible Senior Notes (Carrying Value) | $70,082 | $0 |
| Total Net Assets | $422,050 | $412,531 |
| Net Asset Value (NAV) per Share | $9.61 | $9.50 |
| Shares Outstanding | 43,908 | 43,444 |
Results of Operations (Nine Months Ended Sept 30, 2011)
- Total Investment Income: $58,655 (Interest: $50,932; Fees: $7,723)
- Total Operating Expenses: $29,898
- Net Investment Income: $28,757
- Net Realized Gain on Investments: $3,429
- Net Unrealized Depreciation on Investments: $(2,823)
- Net Increase in Net Assets from Operations: $29,363
- Net Investment Income per Share (Basic): $0.67
- Change in Net Assets per Share (Basic): $0.67
Material Changes vs. Prior Period
- Portfolio Growth: Total investment portfolio value increased by approximately $104.4 million (22.1%) from $472.0 million to $576.5 million, driven by new debt commitments and restructured loans.
- Debt Issuance: In April 2011, the company issued $75.0 million in 6.00% Convertible Senior Notes due 2016. This significantly increased total liabilities and interest expense.
- Investment Income: Interest income for the nine months ended Sept 30, 2011, rose to $50.9 million from $38.1 million in the prior year period, attributable to a larger average interest-earning portfolio and income from early repayments.
- Operating Expenses: Increased to $29.9 million from $22.0 million year-over-year, primarily due to interest and fee expenses related to the new Convertible Senior Notes and increased employee compensation.
- Realized Gains/Losses: The company recognized net realized gains of $3.4 million for the nine months ended Sept 30, 2011, compared to net realized losses of $15.1 million in the same period in 2010. The 2011 gains were driven by the sale of common stock in public portfolio companies, partially offset by losses from liquidated investments.
- Unrealized Depreciation: Net unrealized depreciation of $2.8 million was recorded for the nine months ended Sept 30, 2011, compared to $12.2 million in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management anticipates yield compression as 2011 concludes but believes the company is well-positioned due to its liquidity and pipeline. The company plans to fund unfunded commitments ($148.2 million) and non-binding term sheets ($136.0 million) using cash flows from operations, SBA debentures, and credit facilities. The company intends to maintain its quarterly dividend policy, with a recent declaration of $0.22 per share.
Risks and Contingencies
- Internal Control Material Weakness: The company identified a material weakness in internal control over financial reporting related to manual input errors in fair value calculations. While remediation steps (additional review layers, hiring) have been implemented, management concluded that controls were not yet effective as of September 30, 2011, due to insufficient evidence of sustained effectiveness.
- Concentration Risk: Significant investments in specific portfolio companies (e.g., Aveo Pharmaceuticals, Women's Marketing, Tectura Corporation) represent over 5% of net assets each. Failure of these companies could materially impact results.
- Regulatory and Economic Risks: Investments in life sciences and clean tech are subject to regulatory approval risks and economic volatility. The company faces risks related to SBA compliance for its SBIC subsidiaries and potential constraints from credit facility covenants.
- Interest Rate Risk: Approximately 91.1% of the loan portfolio is at variable rates. Rising interest rates could increase borrowing costs, though this may be offset by higher yields on variable-rate assets.
Unusual Items
- Infologix Sale: The sale of the control investment in Infologix, Inc. in January 2011 resulted in approximately $8.3 million in realized gains and a reversal of $8.4 million in unrealized depreciation.
- Non-Accrual Status: As of September 30, 2011, one portfolio company was on non-accrual status with a fair value of zero. Two loans were on non-accrual status as of December 31, 2010.
Investor Verification Checklist
- Internal Control Remediation: Verify the status of remediation efforts regarding the material weakness in fair value calculations and the timeline for declaring controls effective.
- Convertible Notes Impact: Assess the long-term impact of the $75 million Convertible Senior Notes on interest expense and potential dilution upon conversion.
- Portfolio Concentration: Review the performance and risk profile of the top 7 portfolio companies, which collectively represent over 44% of net assets.
- SBIC Leverage Capacity: Confirm the ability of HT II and HT III to draw remaining SBA leverage ($36.25 million available for HT III) to fund future commitments.
- Dividend Sustainability: Monitor the ratio of net investment income to dividends declared to ensure the company can maintain its distribution policy without returning capital.